Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 1/20 | 0.57 |
| ▸ | THRB | P10828 | 1/20 | 0.57 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.51 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.50 |
| ▸ | PPARA | Q07869 | 2/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | BID | P55957 | 3/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.41 |
| ▸ | BCL2L1 | Q07817 | 2/20 | 0.41 |
| ▸ | BAK1 | Q16611 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethylene Glycol SCHEMBL11666399 | 1.00 | THRA (0.57) | THRATHRBLIPGALOX5PTGS2 | |
| Ethylene Glycol SCHEMBL11057177 | 1.00 | THRA (0.57) | THRATHRBLIPGALOX5PTGS2 | |
| Ethylene Glycol SCHEMBL21373973 | 1.00 | THRA (0.57) | THRATHRBLIPGALOX5PTGS2 | |
| Ethylene Glycol SCHEMBL11667182 | 1.00 | THRA (0.57) | THRATHRBLIPGALOX5PTGS2 | |
| Ethylene Glycol SCHEMBL2169345 | 1.00 | THRA (0.57) | THRATHRBLIPGALOX5PTGS2 | |
| Ethylene Glycol SCHEMBL487727 | 0.97 | THRA (0.56) | THRATHRBLIPGALOX5PTGS2 | |
| Ethylene Glycol SCHEMBL3259231 | 0.97 | THRA (0.56) | THRATHRBLIPGALOX5PTGS2 | |
| Ethylene Glycol SCHEMBL20582190 | 0.97 | THRA (0.56) | THRATHRBLIPGALOX5PTGS2 | |
| Ethylene Glycol SCHEMBL11574529 | 0.97 | THRA (0.56) | THRATHRBLIPGALOX5PTGS2 | |
| Ethylene SCHEMBL4621010 | 0.93 | THRA (0.59) | THRATHRBLIPGALOX5PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3463317-A1 | METHOD FOR PREPARATION OF QUICK DISSOLVING THIN FILMS CONTAINING BIOACTIVE MATERIAL WITH ENHANCED THERMAL STABILITY | Aridis Pharmaceuticals, Inc. (US) | 2019-04-10 | — | — | EP | claimed |
| WO-2017214187-A1 | METHOD FOR PREPARATION OF QUICK DISSOLVING THIN FILMS CONTAINING BIOACTIVE MATERIAL WITH ENHANCED THERMAL STABILITY | ARIDIS PHARMACEUTICALS, INC. (US) | 2017-12-14 | — | — | WO | claimed |
| US-20140356396-A1 | ROTAVIRUS PREPARATIONS WITH EXCESS CALCIUM IONS AND HIGH VISCOSITIES THAT ENSURE VIABILITY AT ELEVATED TEMPERATURES | PULLIAM BRIAN L (US) | 2014-12-04 | — | — | US | claimed |
| EP-2747777-A2 | ROTAVIRUS PREPARATIONS WITH EXCESS CALCIUM IONS AND HIGH VISCOSITIES THAT ENSURE VACCINE VIABILITY AT ELEVATED TEMPERATURES | Pulliam, Brian (US) | 2014-07-02 | — | — | EP | claimed |
| EP-2197283-B1 | FORMULATIONS FOR PRESERVATION OF ROTA VIRUS | ARIDIS PHARMACEUTICALS (US) | 2013-07-17 | — | — | EP | claimed |
| WO-2013029033-A2 | ROTAVIRUS PREPARATIONS WITH EXCESS CALCIUM IONS AND HIGH VISCOSITIES THAT ENSURE VACCINE VIABILITY AT ELEVATED TEMPERATURES | PULLIAM BRIAN (US) | 2013-02-28 | — | — | WO | claimed |
| US-8241886-B2 | Formulations for preservation of rotavirus | ARIDIS PHARMACEUTICALS (US) | 2012-08-14 | — | — | US | claimed |
| US-20100226939-A1 | FORMULATIONS FOR PRESERVATION OF ROTAVIRUS | STREETERVILLE CAPITAL, LLC | 2010-09-09 | — | — | US | claimed |
| EP-2197283-A2 | FORMULATIONS FOR PRESERVATION OF ROTA VIRUS | Aridis Pharmaceuticals (US) | 2010-06-23 | — | — | EP | claimed |
| WO-2009042202-A2 | FORMULATIONS FOR PRESERVATION OF ROTA VIRUS | ARIDIS PHARMACEUTICALS (US) | 2009-04-02 | — | — | WO | claimed |
| EP-2029095-A2 | PROCESS FOR STRAIGHTENING KERATIN FIBRES WITH A HEATING MEANS AND DENATURING AGENTS | L'Oréal (FR) | 2009-03-04 | — | — | EP | claimed |
| WO-2007135297-A2 | PROCESS FOR STRAIGHTENING KERATIN FIBRES WITH A HEATING MEANS AND DENATURING AGENTS | L'OREAL (FR) | 2007-11-29 | — | — | WO | claimed |
| US-11633472-B2 | Compositions | GLAXOSMITHKLINE BIOLOGICALS SA | 2023-04-25 | — | — | US | disclosed |
| US-20230017661-A1 | COMPOSITIONS AND MODULAR NANO- AND MICROPARTICLES FOR THE DELIVERY OF VARIOUS AGENTS AND USE THEREOF | VERI NANO INC. (US) | 2023-01-19 | — | — | US | disclosed |
| US-11399611-B2 | Process for straightening keratin fibres with a heating means and denaturing agents | L'OREAL (FR) | 2022-08-02 | — | — | US | disclosed |
| US-20210322537-A1 | Method For Preparation of Quick Dissolving Thin Films Containing Bioactive Material With Enhanced Thermal Stability | STREETERVILLE CAPITAL, LLC | 2021-10-21 | — | — | US | disclosed |
| WO-1996032124-A1 | MODIFIED LYSINE OR ARGININE CONTAINING PROTEINS AND PEPTIDES | NEW YORK BLOOD CENTER (US) | 1996-10-17 | — | — | WO | disclosed |
| US-5547833-A | Radial flow assay, delivering member, test kit, and methods | INTRACEL CORPORATION (US) | 1996-08-20 | — | — | US | disclosed |
| WO-1995018970-A1 | RADIAL FLOW ASSAY | INTRACEL CORPORATION (US) | 1995-07-13 | — | — | WO | disclosed |
| US-5384128-A | Method of and compounds for treatment for cystic fibrosis | UNIVERSITY OF ALABAMA RESEARCH FOUNDATION (US) | 1995-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11399611-B2 | Process for straightening keratin fibres with a heating means and denaturing agents | KRT18, KRTCAP2, TUBB4A | THRA 3388/4885THRB 4285/4885LIPG 4336/4885 |
| US-20230017661-A1 | COMPOSITIONS AND MODULAR NANO- AND MICROPARTICLES FOR THE DELIVERY OF VARIOUS AGENTS AND USE THEREOF | CD47, CD44, CHMP4B | THRA 3837/4885THRB 4573/4885LIPG 408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.